BioSight
Back
Editas Medicine, Inc. logo

EDIT

NASDAQCAMBRIDGE, MA
Editas Medicine, Inc.

Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapeutics across rare genetic diseases and oncology. The company relies on third-party contract manufacturing organizations for preclinical and clinical materials, as well as contract research organizations to conduct clinical trials, with specific named programs not detailed in this risk disclosure excerpt. Editas depends on collaborations with pharmaceutical partners to advance its pipeline and bring product candidates to market, though the excerpt does not identify individual lead programs or their current development status.

$3.00+81.82%1Y
EDIT · daily close · illustrative · 0 catalysts marked
1Y high$4.151Y low$1.33range$2.82(212%)past catalysts

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.